188 related articles for article (PubMed ID: 37027928)
1. Multi-omics integrated circulating cell-free DNA genomic signatures enhanced the diagnostic performance of early-stage lung cancer and postoperative minimal residual disease.
Li Y; Jiang G; Wu W; Yang H; Jin Y; Wu M; Liu W; Yang A; Chervova O; Zhang S; Zheng L; Zhang X; Du F; Kanu N; Wu L; Yang F; Wang J; Chen K
EBioMedicine; 2023 May; 91():104553. PubMed ID: 37027928
[TBL] [Abstract][Full Text] [Related]
2. Sensitive detection of stage I lung adenocarcinoma using plasma cell-free DNA breakpoint motif profiling.
Guo W; Chen X; Liu R; Liang N; Ma Q; Bao H; Xu X; Wu X; Yang S; Shao Y; Tan F; Xue Q; Gao S; He J
EBioMedicine; 2022 Jul; 81():104131. PubMed ID: 35780566
[TBL] [Abstract][Full Text] [Related]
3. Enhanced Detection of Landmark Minimal Residual Disease in Lung Cancer Using Cell-free DNA Fragmentomics.
Wang S; Xia Z; You J; Gu X; Meng F; Chen P; Tang W; Bao H; Zhang J; Wu X; Shao Y; Wang J; Zuo X; Xu L; Yin R
Cancer Res Commun; 2023 May; 3(5):933-942. PubMed ID: 37377889
[TBL] [Abstract][Full Text] [Related]
4. Combining variant detection and fragment length analysis improves detection of minimal residual disease in postsurgery circulating tumour DNA of stage II-IIIA NSCLC patients.
Vessies DCL; Schuurbiers MMF; van der Noort V; Schouten I; Linders TC; Lanfermeijer M; Ramkisoensing KL; Hartemink KJ; Monkhorst K; van den Heuvel MM; van den Broek D
Mol Oncol; 2022 Jul; 16(14):2719-2732. PubMed ID: 35674097
[TBL] [Abstract][Full Text] [Related]
5. Individualized tumor-informed circulating tumor DNA analysis for postoperative monitoring of non-small cell lung cancer.
Chen K; Yang F; Shen H; Wang C; Li X; Chervova O; Wu S; Qiu F; Peng D; Zhu X; Chuai S; Beck S; Kanu N; Carbone D; Zhang Z; Wang J
Cancer Cell; 2023 Oct; 41(10):1749-1762.e6. PubMed ID: 37683638
[TBL] [Abstract][Full Text] [Related]
6. Response prediction and risk stratification of patients with rectal cancer after neoadjuvant therapy through an analysis of circulating tumour DNA.
Liu W; Li Y; Tang Y; Song Q; Wang J; Li N; Chen S; Shi J; Wang S; Li Y; Jiao Y; Zeng Y; Jin J
EBioMedicine; 2022 Apr; 78():103945. PubMed ID: 35306340
[TBL] [Abstract][Full Text] [Related]
7. Circulating tumor DNA-minimal residual disease: An up-and-coming nova in resectable non-small-cell lung cancer.
Li FQ; Cui JW
Crit Rev Oncol Hematol; 2022 Nov; 179():103800. PubMed ID: 36031171
[TBL] [Abstract][Full Text] [Related]
8. Perioperative ctDNA-Based Molecular Residual Disease Detection for Non-Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1).
Xia L; Mei J; Kang R; Deng S; Chen Y; Yang Y; Feng G; Deng Y; Gan F; Lin Y; Pu Q; Ma L; Lin F; Yuan Y; Hu Y; Guo C; Liao H; Liu C; Zhu Y; Wang W; Liu Z; Xu Y; Li K; Li C; Li Q; He J; Chen W; Zhang X; Kou Y; Wang Y; Wu Z; Che G; Chen L; Liu L
Clin Cancer Res; 2022 Aug; 28(15):3308-3317. PubMed ID: 34844976
[TBL] [Abstract][Full Text] [Related]
9. Accurate classification of pulmonary nodules by a combined model of clinical, imaging, and cell-free DNA methylation biomarkers: a model development and external validation study.
He J; Wang B; Tao J; Liu Q; Peng M; Xiong S; Li J; Cheng B; Li C; Jiang S; Qiu X; Yang Y; Ye Z; Zeng F; Zhang J; Liu D; Li W; Chen Z; Zeng Q; Fan JB; Liang W
Lancet Digit Health; 2023 Oct; 5(10):e647-e656. PubMed ID: 37567793
[TBL] [Abstract][Full Text] [Related]
10. Potential clinical utility of liquid biopsy in early-stage non-small cell lung cancer.
Shen H; Jin Y; Zhao H; Wu M; Zhang K; Wei Z; Wang X; Wang Z; Li Y; Yang F; Wang J; Chen K
BMC Med; 2022 Dec; 20(1):480. PubMed ID: 36514063
[TBL] [Abstract][Full Text] [Related]
11. [MinerVa: A high performance bioinformatic algorithm for the detection of minimal residual disease in solid tumors].
Yang P; Zhang Y; Xia L; Mei J; Fan R; Huang Y; Liu L; Chen W
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2023 Apr; 40(2):313-319. PubMed ID: 37139763
[TBL] [Abstract][Full Text] [Related]
12. Multidimensional Cell-Free DNA Fragmentomic Assay for Detection of Early-Stage Lung Cancer.
Wang S; Meng F; Li M; Bao H; Chen X; Zhu M; Liu R; Xu X; Yang S; Wu X; Shao Y; Xu L; Yin R
Am J Respir Crit Care Med; 2023 May; 207(9):1203-1213. PubMed ID: 36346614
[No Abstract] [Full Text] [Related]
13. Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer.
Shields MD; Chen K; Dutcher G; Patel I; Pellini B
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012272
[TBL] [Abstract][Full Text] [Related]
14. Circulating microbiome DNA as biomarkers for early diagnosis and recurrence of lung cancer.
Chen H; Ma Y; Xu J; Wang W; Lu H; Quan C; Yang F; Lu Y; Wu H; Qiu M
Cell Rep Med; 2024 Apr; 5(4):101499. PubMed ID: 38582085
[TBL] [Abstract][Full Text] [Related]
15. In-depth cell-free DNA sequencing reveals genomic landscape of Hodgkin's lymphoma and facilitates ultrasensitive residual disease detection.
Sobesky S; Mammadova L; Cirillo M; Drees EEE; Mattlener J; Dörr H; Altmüller J; Shi Z; Bröckelmann PJ; Weiss J; Kreissl S; Sasse S; Ullrich RT; Reinke S; Klapper W; Gerhard-Hartmann E; Rosenwald A; Roemer MGM; Nürnberg P; Hagenbeek A; Zijlstra JM; Pegtel DM; Engert A; Borchmann P; von Tresckow B; Borchmann S
Med; 2021 Oct; 2(10):1171-1193.e11. PubMed ID: 35590205
[TBL] [Abstract][Full Text] [Related]
16. Early detection of the major male cancer types in blood-based liquid biopsies using a DNA methylation panel.
Constâncio V; Nunes SP; Moreira-Barbosa C; Freitas R; Oliveira J; Pousa I; Oliveira J; Soares M; Dias CG; Dias T; Antunes L; Henrique R; Jerónimo C
Clin Epigenetics; 2019 Dec; 11(1):175. PubMed ID: 31791387
[TBL] [Abstract][Full Text] [Related]
17. Machine learning enables detection of early-stage colorectal cancer by whole-genome sequencing of plasma cell-free DNA.
Wan N; Weinberg D; Liu TY; Niehaus K; Ariazi EA; Delubac D; Kannan A; White B; Bailey M; Bertin M; Boley N; Bowen D; Cregg J; Drake AM; Ennis R; Fransen S; Gafni E; Hansen L; Liu Y; Otte GL; Pecson J; Rice B; Sanderson GE; Sharma A; St John J; Tang C; Tzou A; Young L; Putcha G; Haque IS
BMC Cancer; 2019 Aug; 19(1):832. PubMed ID: 31443703
[TBL] [Abstract][Full Text] [Related]
18. Circulating tumor DNA integrating tissue clonality detects minimal residual disease in resectable non-small-cell lung cancer.
Wang S; Li M; Zhang J; Xing P; Wu M; Meng F; Jiang F; Wang J; Bao H; Huang J; Ren B; Yu M; Qiu N; Li H; Yuan F; Zhang Z; Jia H; Lu X; Zhang S; Wang X; Xu Y; Xia W; Liu T; Xu W; Xu X; Sun M; Wu X; Shao Y; Wang Q; Dai J; Qiu M; Wang J; Zhang Q; Xu L; Shen H; Yin R
J Hematol Oncol; 2022 Oct; 15(1):137. PubMed ID: 36183093
[TBL] [Abstract][Full Text] [Related]
19. Resectable lung lesions malignancy assessment and cancer detection by ultra-deep sequencing of targeted gene mutations in plasma cell-free DNA.
Peng M; Xie Y; Li X; Qian Y; Tu X; Yao X; Cheng F; Xu F; Kong D; He B; Liu C; Cao F; Yang H; Yu F; Xu C; Tian G
J Med Genet; 2019 Oct; 56(10):647-653. PubMed ID: 30981987
[TBL] [Abstract][Full Text] [Related]
20. Detecting liquid remnants of solid tumors treated with curative intent: Circulating tumor DNA as a biomarker of minimal residual disease (Review).
Chen H; Zhou Q
Oncol Rep; 2023 May; 49(5):. PubMed ID: 37052271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
